Clinical Trial Search

Primary: Prevalence of HCV Seropositivity in Breast Cancer Patients. — 88; 15; 317; 130 Participants — p=0.0027

Primary: The Dynamic Change of HBV DNA — 3.15; 3.14 IU/mL

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 5; 4; 5; 4 Participants

Primary: Number of Participants With Sustained Virological Response at Week 12 (SVR12) — 2; 2 participants

Primary: Number of Subjects Who Completed 24 Weeks of Therapy — 0; 1 Participants

Primary: Improvement in Scores on HCV Knowledge Questionnaire — 18.45; 19; 20.3; 21.75 Improvement in scores

Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05

Primary: Effect of HSV-2 Suppression on HCV Viral Load. — .18; .03 log(IU/mL)

Primary: Sustained Virologic Response (SVR) — 62 percentage of participants

Primary: Point Prevalence of Hepatitis C Infection — 9 percentage of total subjects

Primary: Number of Subjects With Adverse Events as Assessed by CTCAE v5.0 — 9; 13; 3; 16 Participants

Primary: Sero-response to Hepatitis B Surface Antigen — 60; 73.2; 75.4 percentage of participants who resonded — p=0.0440

Primary: 1,3,5 Year-Disease Free Survival (or Recurrence Free Survival) — 11; 13; 25; 34 participants

Primary: Sustained Virologic Response After Treatment — 24 Participants

Primary: The Change in Serum Alanine Aminotransferase Level From Baseline to 12 Weeks — 77.5; 105.5 IU/L

Primary: Incidence of Adverse Events (AEs) — 4; 3; 4; 5 Participants

Primary: The Incidence of Participants With Treatment-Emergent Adverse Events (TEAEs) and ≥Grade 3 Study Vaccine-related Adverse Events Following Study Vaccination — 1; 1; 2; 1…

Primary: Intrahepatic and Plasma HCV Viral Kinetics — 6.5; 4.9; 3.2; 4.2 log transformed copies/ml

Primary: Mean Log Change in Viral Load From Baseline (Day 1) to Day 28 — 0.30; 0.00; 0.18; 0.04 copies/mL on log scale

Primary: Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment — 11; 7 participants

Primary: Number of Drinking Days in the Past Two Weeks — 8.6; 8.9; 6.8; 7.1 Number of Drinking Days/2 weeks — p=<0.01

Primary: Number of Participants With Sustained Virologic Response — 70 Participants

Primary: HCV Antibody Test — 574 Participants

Primary: HBsAG Prevalence — 22 Participants

Primary: Adherence to Recommended HBV Monitoring: Doctor's Visits — 159; 100; 170; 147 Participants

Primary: Quality of Well-being Scale - Self-Administered (QWB-SA) — .534; .501; .600; .504 units on a scale

Primary: Serum Aflatoxin Level in Liver Cancer Patients — 7.96; 6.10; 4.13 ng\ml

Primary: Change of Serum Hepatitis B Surface Antigen (HBsAg as Measured in log10 IU/mL) Level as an Indicator of Antiviral Activity of Ledipasvir and/or Sofosbuvir in Subjects…

Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants

Primary: Maintained Combined Response (Virological, Biochemical and Histological Response). — 15; 6; 7; 13 participants — p=0.0294